EPT1044
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- e1_e2
- E2
- umap1_2d
- -5.512095461
- umap2_2d
- -0.371932762
- umap1_3d
- -0.16844367
- umap2_3d
- 2.734030714
- umap3_3d
- 0.240605314
- dataset
- EPN-Toronto
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- HYPOXIA+0.420
- P53_PATHWAY+0.350
- TGF_BETA_SIGNALING+0.340
- UV_RESPONSE_UP+0.340
- XENOBIOTIC_METABOLISM+0.340
- COAGULATION+0.330
- INFLAMMATORY_RESPONSE+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.440
- G2M_CHECKPOINT-0.360
- SPERMATOGENESIS-0.320
- E2F_TARGETS-0.310
- MYC_TARGETS_V1-0.140
- HEDGEHOG_SIGNALING-0.120
- MITOTIC_SPINDLE-0.110
- PROTEIN_SECRETION-0.110
- ANDROGEN_RESPONSE-0.100
- UV_RESPONSE_DN-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_RHD7XPNP | EPN | Posterior Fossa EPN | 0.890 |
| 2 | SRR1407315 | GTEX | — | 0.862 |
| 3 | SRR3147740 | — | — | 0.860 |
| 4 | BS_4Y6BCYK5 | pilocytic astrocytoma | — | 0.859 |
| 5 | BS_YCREDZTJ | low-grade glioma | — | 0.858 |
| 6 | BS_WG203ECV | pilocytic astrocytoma | — | 0.847 |
| 7 | SRR1331597 | GTEX | — | 0.846 |
| 8 | cc158c27-a2f0-4403-ae01-913bfcc623cc | — | — | 0.844 |
| 9 | BS_HC5M8JTC | low-grade glioma | — | 0.841 |
| 10 | BS_N1E0H8YQ | low-grade glioma | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |